| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Iodide Peroxidase | 106 | 2023 | 111 | 20.730 |
Why?
|
| Hypothyroidism | 58 | 2023 | 69 | 15.680 |
Why?
|
| Thyroxine | 72 | 2023 | 80 | 13.930 |
Why?
|
| Triiodothyronine | 84 | 2023 | 91 | 13.610 |
Why?
|
| Thyroid Hormones | 54 | 2023 | 57 | 12.140 |
Why?
|
| Thyrotropin | 39 | 2023 | 49 | 5.390 |
Why?
|
| Animals | 156 | 2023 | 3287 | 5.260 |
Why?
|
| Adipose Tissue, Brown | 40 | 2022 | 40 | 4.630 |
Why?
|
| Thyroid Gland | 28 | 2021 | 42 | 4.430 |
Why?
|
| Signal Transduction | 26 | 2021 | 403 | 3.670 |
Why?
|
| Energy Metabolism | 18 | 2020 | 42 | 3.510 |
Why?
|
| Hormone Replacement Therapy | 15 | 2022 | 32 | 3.510 |
Why?
|
| Mice | 68 | 2023 | 1236 | 3.200 |
Why?
|
| Humans | 143 | 2023 | 23331 | 2.530 |
Why?
|
| Obesity | 17 | 2016 | 293 | 2.430 |
Why?
|
| Thermogenesis | 15 | 2022 | 15 | 2.310 |
Why?
|
| Mice, Knockout | 40 | 2021 | 279 | 2.180 |
Why?
|
| Thyroid Diseases | 7 | 2021 | 11 | 2.110 |
Why?
|
| Liver | 17 | 2023 | 142 | 1.940 |
Why?
|
| Adipose Tissue | 11 | 2020 | 72 | 1.730 |
Why?
|
| Male | 113 | 2022 | 12629 | 1.730 |
Why?
|
| Homeostasis | 12 | 2021 | 65 | 1.720 |
Why?
|
| Membrane Proteins | 17 | 2014 | 151 | 1.550 |
Why?
|
| Fatty Liver | 9 | 2019 | 26 | 1.520 |
Why?
|
| Gene Expression Regulation | 16 | 2019 | 233 | 1.460 |
Why?
|
| Muscle, Skeletal | 10 | 2017 | 323 | 1.400 |
Why?
|
| Rats | 52 | 2022 | 625 | 1.330 |
Why?
|
| Quality of Life | 8 | 2023 | 560 | 1.320 |
Why?
|
| Hypothalamus | 7 | 2022 | 13 | 1.320 |
Why?
|
| Carrier Proteins | 18 | 2009 | 89 | 1.310 |
Why?
|
| Polymorphism, Genetic | 4 | 2021 | 47 | 1.250 |
Why?
|
| Hypothalamo-Hypophyseal System | 10 | 2022 | 22 | 1.230 |
Why?
|
| RNA, Messenger | 29 | 2017 | 285 | 1.200 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2022 | 166 | 1.150 |
Why?
|
| Receptors, Thyroid Hormone | 12 | 2019 | 12 | 1.130 |
Why?
|
| Gene Expression | 15 | 2021 | 178 | 1.110 |
Why?
|
| Endoplasmic Reticulum Stress | 3 | 2018 | 4 | 1.100 |
Why?
|
| Mice, Inbred C57BL | 25 | 2021 | 360 | 1.080 |
Why?
|
| Lipid Metabolism | 7 | 2020 | 32 | 1.050 |
Why?
|
| Pituitary Gland | 6 | 2023 | 14 | 1.030 |
Why?
|
| Iodine Radioisotopes | 5 | 2023 | 12 | 1.030 |
Why?
|
| Endoplasmic Reticulum | 11 | 2018 | 25 | 1.020 |
Why?
|
| Neurons | 8 | 2023 | 272 | 1.000 |
Why?
|
| Thyroid Function Tests | 8 | 2023 | 12 | 0.990 |
Why?
|
| Gene Expression Regulation, Developmental | 7 | 2021 | 34 | 0.990 |
Why?
|
| Ubiquitin-Protein Ligases | 6 | 2015 | 26 | 0.980 |
Why?
|
| Iodine | 5 | 2020 | 5 | 0.970 |
Why?
|
| Cells, Cultured | 22 | 2021 | 481 | 0.970 |
Why?
|
| Transcriptome | 5 | 2023 | 55 | 0.970 |
Why?
|
| Brain | 8 | 2023 | 1200 | 0.930 |
Why?
|
| Body Temperature Regulation | 12 | 2012 | 19 | 0.930 |
Why?
|
| Mitochondrial Proteins | 22 | 2014 | 38 | 0.930 |
Why?
|
| Amiodarone | 2 | 2018 | 3 | 0.930 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2018 | 27 | 0.910 |
Why?
|
| Ubiquitination | 5 | 2018 | 15 | 0.870 |
Why?
|
| Symporters | 3 | 2023 | 5 | 0.850 |
Why?
|
| Uncoupling Protein 1 | 22 | 2022 | 22 | 0.840 |
Why?
|
| Cell Line | 17 | 2011 | 254 | 0.840 |
Why?
|
| Proteins | 8 | 2005 | 54 | 0.830 |
Why?
|
| Fasting | 7 | 2022 | 19 | 0.830 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2023 | 12 | 0.830 |
Why?
|
| Female | 57 | 2023 | 13124 | 0.820 |
Why?
|
| Proteasome Endopeptidase Complex | 9 | 2013 | 21 | 0.800 |
Why?
|
| Ubiquitin | 7 | 2013 | 29 | 0.790 |
Why?
|
| Insulin-Secreting Cells | 2 | 2014 | 11 | 0.790 |
Why?
|
| Euthyroid Sick Syndromes | 5 | 2022 | 7 | 0.780 |
Why?
|
| Voice | 1 | 2022 | 5 | 0.780 |
Why?
|
| Adult | 31 | 2023 | 7070 | 0.750 |
Why?
|
| Cholesterol | 6 | 2020 | 57 | 0.730 |
Why?
|
| Zinc | 1 | 2021 | 39 | 0.720 |
Why?
|
| Hypercholesterolemia | 2 | 2020 | 20 | 0.720 |
Why?
|
| Glucose | 5 | 2014 | 43 | 0.710 |
Why?
|
| Norepinephrine | 14 | 2016 | 30 | 0.690 |
Why?
|
| Hepatocytes | 2 | 2023 | 10 | 0.690 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 61 | 0.690 |
Why?
|
| Forkhead Box Protein O1 | 2 | 2018 | 6 | 0.680 |
Why?
|
| Precision Medicine | 1 | 2020 | 24 | 0.660 |
Why?
|
| Insulin | 8 | 2014 | 78 | 0.650 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 230 | 0.640 |
Why?
|
| Rats, Wistar | 18 | 2022 | 54 | 0.640 |
Why?
|
| Muscle Fibers, Skeletal | 4 | 2015 | 39 | 0.630 |
Why?
|
| Patient Satisfaction | 2 | 2022 | 258 | 0.630 |
Why?
|
| Diet, High-Fat | 5 | 2016 | 12 | 0.620 |
Why?
|
| Ion Channels | 21 | 2014 | 205 | 0.620 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2019 | 6 | 0.610 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 56 | 0.610 |
Why?
|
| Unfolded Protein Response | 1 | 2018 | 1 | 0.600 |
Why?
|
| Mice, Transgenic | 13 | 2018 | 176 | 0.590 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2018 | 2 | 0.590 |
Why?
|
| Endocrine System Diseases | 1 | 2018 | 4 | 0.590 |
Why?
|
| Thyroid Hormone Receptors beta | 6 | 2010 | 6 | 0.590 |
Why?
|
| Animals, Newborn | 6 | 2021 | 41 | 0.580 |
Why?
|
| Cell Nucleus | 7 | 2018 | 69 | 0.560 |
Why?
|
| Kinetics | 12 | 2022 | 179 | 0.560 |
Why?
|
| Myocardium | 4 | 2017 | 100 | 0.550 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2015 | 31 | 0.550 |
Why?
|
| Oxygen Consumption | 11 | 2013 | 52 | 0.550 |
Why?
|
| Middle Aged | 29 | 2021 | 8055 | 0.540 |
Why?
|
| Molecular Sequence Data | 15 | 2015 | 188 | 0.540 |
Why?
|
| Bone Density | 5 | 2003 | 136 | 0.540 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 161 | 0.530 |
Why?
|
| Self Report | 1 | 2018 | 195 | 0.520 |
Why?
|
| Acetates | 4 | 2010 | 16 | 0.520 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 3 | 2015 | 5 | 0.520 |
Why?
|
| Cross-Sectional Studies | 6 | 2023 | 774 | 0.520 |
Why?
|
| Time Factors | 18 | 2020 | 1289 | 0.510 |
Why?
|
| Aged | 23 | 2023 | 7552 | 0.510 |
Why?
|
| Mitochondria | 10 | 2017 | 54 | 0.500 |
Why?
|
| Cold Temperature | 15 | 2016 | 27 | 0.480 |
Why?
|
| Acclimatization | 6 | 2010 | 6 | 0.480 |
Why?
|
| Pericardium | 2 | 2015 | 20 | 0.470 |
Why?
|
| Biomarkers | 5 | 2020 | 487 | 0.470 |
Why?
|
| HEK293 Cells | 6 | 2020 | 61 | 0.470 |
Why?
|
| Amino Acid Substitution | 4 | 2018 | 20 | 0.460 |
Why?
|
| Models, Molecular | 8 | 2015 | 79 | 0.460 |
Why?
|
| Body Composition | 6 | 2013 | 64 | 0.460 |
Why?
|
| Hyperthyroidism | 6 | 2022 | 10 | 0.450 |
Why?
|
| Cytoplasm | 3 | 2013 | 33 | 0.450 |
Why?
|
| Lipids | 7 | 2021 | 45 | 0.450 |
Why?
|
| Models, Biological | 8 | 2013 | 306 | 0.440 |
Why?
|
| Neuroglia | 2 | 2015 | 39 | 0.440 |
Why?
|
| Glucose Intolerance | 2 | 2011 | 3 | 0.440 |
Why?
|
| Bone and Bones | 5 | 2021 | 110 | 0.430 |
Why?
|
| Adipocytes | 9 | 2015 | 22 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2015 | 324 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 14 | 2012 | 312 | 0.430 |
Why?
|
| Amino Acid Sequence | 12 | 2015 | 149 | 0.430 |
Why?
|
| Adenosine Triphosphatases | 2 | 2013 | 8 | 0.420 |
Why?
|
| Protein Binding | 7 | 2016 | 115 | 0.420 |
Why?
|
| Repressor Proteins | 1 | 2013 | 33 | 0.410 |
Why?
|
| Hippocampus | 4 | 2018 | 200 | 0.410 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 99 | 0.410 |
Why?
|
| Benzhydryl Compounds | 2 | 2010 | 3 | 0.410 |
Why?
|
| Dexamethasone | 1 | 2013 | 34 | 0.410 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 73 | 0.400 |
Why?
|
| Critical Illness | 3 | 2020 | 110 | 0.400 |
Why?
|
| Glucocorticoids | 1 | 2013 | 60 | 0.400 |
Why?
|
| Dimerization | 4 | 2008 | 19 | 0.400 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 127 | 0.400 |
Why?
|
| Diet | 7 | 2019 | 181 | 0.390 |
Why?
|
| Triglycerides | 5 | 2019 | 54 | 0.390 |
Why?
|
| Research Design | 1 | 2013 | 157 | 0.380 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2012 | 1 | 0.380 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 8 | 0.380 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2012 | 1 | 0.380 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 9 | 2015 | 132 | 0.370 |
Why?
|
| Thyrotropin-Releasing Hormone | 9 | 2015 | 11 | 0.370 |
Why?
|
| Thyroid Hormone Receptors alpha | 2 | 2011 | 2 | 0.370 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2011 | 2 | 0.370 |
Why?
|
| United States | 4 | 2023 | 1829 | 0.370 |
Why?
|
| Basal Metabolism | 5 | 2016 | 7 | 0.370 |
Why?
|
| Dietary Fats | 8 | 2013 | 38 | 0.360 |
Why?
|
| Temperature | 5 | 2011 | 58 | 0.350 |
Why?
|
| Cysteine Endopeptidases | 5 | 2002 | 11 | 0.350 |
Why?
|
| Multienzyme Complexes | 5 | 2002 | 30 | 0.350 |
Why?
|
| Taurochenodeoxycholic Acid | 1 | 2011 | 1 | 0.350 |
Why?
|
| Phenylbutyrates | 1 | 2011 | 5 | 0.350 |
Why?
|
| Energy Intake | 4 | 2020 | 77 | 0.340 |
Why?
|
| Transcription Factors | 6 | 2013 | 149 | 0.340 |
Why?
|
| Cell Membrane | 6 | 2008 | 88 | 0.330 |
Why?
|
| Eating | 6 | 2009 | 45 | 0.330 |
Why?
|
| Rodentia | 1 | 2010 | 6 | 0.330 |
Why?
|
| Anti-Obesity Agents | 1 | 2010 | 4 | 0.330 |
Why?
|
| Astrocytes | 5 | 2018 | 124 | 0.330 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 1038 | 0.320 |
Why?
|
| Enzyme Activation | 7 | 2015 | 110 | 0.320 |
Why?
|
| Protein Conformation | 6 | 2015 | 66 | 0.320 |
Why?
|
| Base Pairing | 1 | 2009 | 1 | 0.320 |
Why?
|
| Mutation, Missense | 2 | 2020 | 24 | 0.320 |
Why?
|
| Contrast Media | 3 | 2017 | 60 | 0.310 |
Why?
|
| Blotting, Western | 8 | 2014 | 132 | 0.300 |
Why?
|
| Gene Frequency | 3 | 2021 | 41 | 0.300 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 1307 | 0.300 |
Why?
|
| Catalysis | 5 | 2008 | 16 | 0.300 |
Why?
|
| Body Weight | 13 | 2010 | 129 | 0.300 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 246 | 0.290 |
Why?
|
| Calorimetry, Indirect | 3 | 2015 | 6 | 0.290 |
Why?
|
| Osteoblasts | 3 | 2015 | 57 | 0.290 |
Why?
|
| Transfection | 7 | 2008 | 120 | 0.290 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 4 | 2017 | 10 | 0.290 |
Why?
|
| Gene Expression Profiling | 4 | 2015 | 112 | 0.290 |
Why?
|
| In Situ Hybridization | 6 | 2015 | 47 | 0.280 |
Why?
|
| Endopeptidases | 3 | 2007 | 20 | 0.280 |
Why?
|
| Lipolysis | 4 | 2020 | 4 | 0.280 |
Why?
|
| Alanine | 4 | 2018 | 11 | 0.280 |
Why?
|
| Acute Kidney Injury | 3 | 2013 | 37 | 0.280 |
Why?
|
| Physical Conditioning, Animal | 3 | 2016 | 5 | 0.280 |
Why?
|
| Phenotype | 7 | 2021 | 257 | 0.270 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 36 | 0.270 |
Why?
|
| DNA Methylation | 2 | 2021 | 128 | 0.270 |
Why?
|
| Threonine | 3 | 2018 | 8 | 0.270 |
Why?
|
| Reference Values | 5 | 2020 | 167 | 0.270 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 98 | 0.270 |
Why?
|
| Sequence Homology, Amino Acid | 5 | 2008 | 34 | 0.270 |
Why?
|
| Kaempferols | 1 | 2007 | 6 | 0.270 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 46 | 0.260 |
Why?
|
| Case-Control Studies | 4 | 2018 | 482 | 0.260 |
Why?
|
| Cerebral Cortex | 4 | 2015 | 127 | 0.260 |
Why?
|
| Physicians | 2 | 2019 | 106 | 0.260 |
Why?
|
| Syndrome | 2 | 2018 | 70 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2016 | 148 | 0.250 |
Why?
|
| Subcellular Fractions | 5 | 2006 | 16 | 0.250 |
Why?
|
| Immunohistochemistry | 7 | 2012 | 338 | 0.250 |
Why?
|
| Cyclic AMP | 7 | 2007 | 31 | 0.250 |
Why?
|
| Trans-Activators | 2 | 2007 | 22 | 0.250 |
Why?
|
| Adiposity | 4 | 2016 | 42 | 0.250 |
Why?
|
| Isoenzymes | 5 | 2008 | 50 | 0.250 |
Why?
|
| Adaptation, Physiological | 5 | 2012 | 43 | 0.250 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2015 | 33 | 0.250 |
Why?
|
| Models, Animal | 4 | 2018 | 100 | 0.240 |
Why?
|
| Muscle Strength | 2 | 2017 | 99 | 0.240 |
Why?
|
| Tissue Extracts | 2 | 2021 | 8 | 0.240 |
Why?
|
| Myocardial Revascularization | 1 | 2005 | 16 | 0.240 |
Why?
|
| Carcinoma 256, Walker | 1 | 2005 | 1 | 0.240 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2005 | 2 | 0.240 |
Why?
|
| Saccharomyces cerevisiae | 2 | 2002 | 20 | 0.240 |
Why?
|
| Double-Blind Method | 3 | 2021 | 382 | 0.240 |
Why?
|
| Membrane Transport Proteins | 3 | 2006 | 38 | 0.240 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2005 | 3 | 0.240 |
Why?
|
| Microarray Analysis | 2 | 2015 | 5 | 0.230 |
Why?
|
| Growth Plate | 1 | 2005 | 13 | 0.230 |
Why?
|
| Triiodothyronine, Reverse | 7 | 2020 | 9 | 0.230 |
Why?
|
| Sympathetic Nervous System | 4 | 2012 | 13 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 115 | 0.230 |
Why?
|
| Prognosis | 7 | 2018 | 740 | 0.230 |
Why?
|
| Treatment Outcome | 8 | 2022 | 2988 | 0.230 |
Why?
|
| Axons | 2 | 2023 | 24 | 0.220 |
Why?
|
| Leptin | 3 | 2018 | 18 | 0.220 |
Why?
|
| Adolescent | 7 | 2021 | 1916 | 0.220 |
Why?
|
| Mutation | 6 | 2007 | 328 | 0.220 |
Why?
|
| Vitamin D | 1 | 2004 | 28 | 0.220 |
Why?
|
| Adipogenesis | 3 | 2015 | 3 | 0.220 |
Why?
|
| Myoblasts | 3 | 2017 | 3 | 0.220 |
Why?
|
| Gene Deletion | 4 | 2015 | 40 | 0.220 |
Why?
|
| Publishing | 1 | 2004 | 31 | 0.220 |
Why?
|
| Diabetes Complications | 2 | 2016 | 44 | 0.210 |
Why?
|
| Organ Specificity | 3 | 2018 | 35 | 0.210 |
Why?
|
| Depression | 2 | 2018 | 369 | 0.210 |
Why?
|
| Periodicals as Topic | 1 | 2004 | 32 | 0.210 |
Why?
|
| Microscopy, Confocal | 2 | 2001 | 81 | 0.210 |
Why?
|
| Organoids | 1 | 2023 | 7 | 0.210 |
Why?
|
| Prospective Studies | 9 | 2022 | 1523 | 0.210 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 23 | 0.210 |
Why?
|
| Swine | 1 | 2023 | 67 | 0.210 |
Why?
|
| Demography | 1 | 2023 | 58 | 0.210 |
Why?
|
| Feedback | 1 | 2023 | 33 | 0.210 |
Why?
|
| Protein Structure, Tertiary | 4 | 2008 | 60 | 0.200 |
Why?
|
| Acetylcysteine | 2 | 2012 | 14 | 0.200 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 26 | 0.200 |
Why?
|
| RNA Interference | 3 | 2009 | 36 | 0.200 |
Why?
|
| Mammals | 2 | 2022 | 20 | 0.200 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 147 | 0.200 |
Why?
|
| Structure-Activity Relationship | 4 | 2015 | 34 | 0.200 |
Why?
|
| Hormones | 3 | 2003 | 15 | 0.200 |
Why?
|
| Endosomes | 1 | 2002 | 8 | 0.200 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 12 | 0.190 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2012 | 53 | 0.190 |
Why?
|
| Mesothelioma | 2 | 2006 | 14 | 0.190 |
Why?
|
| Medicare | 1 | 2023 | 108 | 0.190 |
Why?
|
| Adiponectin | 3 | 2018 | 10 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 41 | 0.190 |
Why?
|
| PPAR gamma | 2 | 2015 | 13 | 0.190 |
Why?
|
| Feedback, Physiological | 3 | 2015 | 13 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2010 | 125 | 0.190 |
Why?
|
| Insulin Resistance | 4 | 2013 | 47 | 0.190 |
Why?
|
| Oxidative Stress | 3 | 2021 | 81 | 0.190 |
Why?
|
| Brazil | 5 | 2021 | 31 | 0.190 |
Why?
|
| Binding Sites | 5 | 2006 | 69 | 0.190 |
Why?
|
| Protein Biosynthesis | 1 | 2002 | 14 | 0.190 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3783 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 236 | 0.180 |
Why?
|
| Hypoglycemic Agents | 4 | 2016 | 35 | 0.180 |
Why?
|
| Transcription, Genetic | 7 | 2015 | 98 | 0.180 |
Why?
|
| Chromatin | 1 | 2021 | 14 | 0.180 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3040 | 0.180 |
Why?
|
| Organ Size | 9 | 2010 | 84 | 0.180 |
Why?
|
| Human Growth Hormone | 2 | 2017 | 4 | 0.180 |
Why?
|
| Podocytes | 1 | 2021 | 37 | 0.180 |
Why?
|
| Birds | 1 | 2001 | 4 | 0.180 |
Why?
|
| Risk Assessment | 4 | 2018 | 565 | 0.170 |
Why?
|
| Lipopolysaccharides | 4 | 2022 | 88 | 0.170 |
Why?
|
| Ubiquitins | 1 | 2000 | 8 | 0.170 |
Why?
|
| Endocrinology | 1 | 2020 | 1 | 0.170 |
Why?
|
| Catalytic Domain | 3 | 2011 | 13 | 0.170 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 57 | 0.170 |
Why?
|
| Adipocytes, Brown | 2 | 2011 | 2 | 0.170 |
Why?
|
| Emergency Treatment | 1 | 2020 | 3 | 0.170 |
Why?
|
| Fatty Acids | 1 | 2020 | 31 | 0.170 |
Why?
|
| Cognition | 4 | 2022 | 941 | 0.170 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 27 | 0.170 |
Why?
|
| Substrate Specificity | 3 | 2020 | 22 | 0.170 |
Why?
|
| Drug Resistance | 1 | 2020 | 45 | 0.170 |
Why?
|
| Analysis of Variance | 4 | 2015 | 235 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 442 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2020 | 129 | 0.160 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 166 | 0.160 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 63 | 0.160 |
Why?
|
| Pregnancy | 3 | 2022 | 322 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2020 | 79 | 0.160 |
Why?
|
| Blood Glucose | 5 | 2016 | 99 | 0.160 |
Why?
|
| Recombinant Proteins | 5 | 2003 | 172 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 262 | 0.160 |
Why?
|
| Base Sequence | 4 | 2006 | 101 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 542 | 0.160 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 62 | 0.150 |
Why?
|
| Immunoprecipitation | 2 | 2012 | 19 | 0.150 |
Why?
|
| Colforsin | 3 | 2004 | 12 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 8 | 0.150 |
Why?
|
| Vaccination Coverage | 1 | 2019 | 2 | 0.150 |
Why?
|
| Binge Drinking | 1 | 2019 | 9 | 0.150 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 291 | 0.150 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2017 | 16 | 0.150 |
Why?
|
| Protein Isoforms | 3 | 2011 | 38 | 0.150 |
Why?
|
| Myosin Heavy Chains | 2 | 2017 | 7 | 0.150 |
Why?
|
| Golgi Apparatus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Tissue Distribution | 3 | 2011 | 33 | 0.150 |
Why?
|
| Coronary Artery Disease | 2 | 2015 | 124 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 154 | 0.150 |
Why?
|
| Nurses | 1 | 2019 | 42 | 0.150 |
Why?
|
| Alcoholism | 1 | 2019 | 65 | 0.150 |
Why?
|
| Spine | 1 | 1999 | 97 | 0.140 |
Why?
|
| Status Epilepticus | 1 | 2018 | 12 | 0.140 |
Why?
|
| Nerve Degeneration | 1 | 2018 | 34 | 0.140 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 517 | 0.140 |
Why?
|
| Ethanol | 1 | 2019 | 82 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2017 | 204 | 0.140 |
Why?
|
| Infusions, Intravenous | 3 | 2012 | 52 | 0.140 |
Why?
|
| Response Elements | 1 | 2018 | 13 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2011 | 4 | 0.140 |
Why?
|
| Genes, Reporter | 1 | 2018 | 22 | 0.140 |
Why?
|
| Thyroidectomy | 6 | 2005 | 18 | 0.140 |
Why?
|
| Pulmonary Fibrosis | 1 | 2017 | 4 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2015 | 58 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2018 | 61 | 0.140 |
Why?
|
| Fatigue | 1 | 2018 | 46 | 0.140 |
Why?
|
| Estrogens | 1 | 1997 | 26 | 0.140 |
Why?
|
| Affect | 1 | 2018 | 58 | 0.140 |
Why?
|
| Bile Acids and Salts | 2 | 2009 | 7 | 0.140 |
Why?
|
| Professional Competence | 1 | 2018 | 38 | 0.140 |
Why?
|
| Emotions | 1 | 2018 | 70 | 0.140 |
Why?
|
| Electric Impedance | 1 | 2017 | 24 | 0.140 |
Why?
|
| Postmenopause | 1 | 1997 | 57 | 0.140 |
Why?
|
| Biological Therapy | 1 | 2017 | 2 | 0.140 |
Why?
|
| Heart | 4 | 2012 | 59 | 0.140 |
Why?
|
| Pediatric Obesity | 1 | 2018 | 43 | 0.140 |
Why?
|
| Internet | 1 | 2018 | 80 | 0.130 |
Why?
|
| Muscle Development | 1 | 2017 | 4 | 0.130 |
Why?
|
| Femur Neck | 1 | 1997 | 16 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2007 | 23 | 0.130 |
Why?
|
| Osteoarthritis | 1 | 2021 | 279 | 0.130 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 18 | 0.130 |
Why?
|
| Molecular Weight | 2 | 2009 | 24 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 43 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 4 | 2009 | 69 | 0.130 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Relative Value Scales | 1 | 2016 | 4 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2011 | 90 | 0.130 |
Why?
|
| Hedgehog Proteins | 2 | 2007 | 6 | 0.130 |
Why?
|
| Hypertension | 1 | 2018 | 162 | 0.130 |
Why?
|
| Young Adult | 1 | 2021 | 1674 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 50 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 4 | 2015 | 126 | 0.130 |
Why?
|
| Rats, Inbred Strains | 10 | 1991 | 25 | 0.130 |
Why?
|
| Awareness | 1 | 2016 | 37 | 0.130 |
Why?
|
| beta-Lactam Resistance | 1 | 2016 | 14 | 0.130 |
Why?
|
| Health Surveys | 1 | 2016 | 79 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 88 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 102 | 0.120 |
Why?
|
| Caffeic Acids | 1 | 2016 | 1 | 0.120 |
Why?
|
| Baccharis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cardiotonic Agents | 2 | 2012 | 9 | 0.120 |
Why?
|
| Coumaric Acids | 1 | 2016 | 2 | 0.120 |
Why?
|
| Protective Agents | 1 | 2016 | 8 | 0.120 |
Why?
|
| Carbapenems | 1 | 2016 | 45 | 0.120 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 44 | 0.120 |
Why?
|
| Linear Models | 5 | 2016 | 192 | 0.120 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 103 | 0.120 |
Why?
|
| Enterobacteriaceae | 1 | 2016 | 41 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 29 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2016 | 19 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2016 | 44 | 0.120 |
Why?
|
| Kidney | 4 | 2004 | 142 | 0.120 |
Why?
|
| Propylthiouracil | 2 | 2001 | 2 | 0.120 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Alleles | 2 | 2014 | 163 | 0.120 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 3 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2015 | 13 | 0.120 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2016 | 55 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2015 | 16 | 0.120 |
Why?
|
| Tropomyosin | 1 | 2015 | 4 | 0.120 |
Why?
|
| Protein Structure, Secondary | 2 | 2007 | 20 | 0.120 |
Why?
|
| Halogenated Diphenyl Ethers | 1 | 2015 | 1 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2015 | 44 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 78 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2006 | 17 | 0.120 |
Why?
|
| Anxiety | 1 | 2016 | 143 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2013 | 36 | 0.120 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 55 | 0.120 |
Why?
|
| Glutathione Reductase | 1 | 2015 | 5 | 0.120 |
Why?
|
| Apoptosis | 2 | 2018 | 198 | 0.120 |
Why?
|
| Echocardiography, Doppler, Pulsed | 2 | 2006 | 3 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2015 | 55 | 0.110 |
Why?
|
| Microscopy, Electron | 2 | 2012 | 61 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2015 | 36 | 0.110 |
Why?
|
| Infection Control | 1 | 2016 | 169 | 0.110 |
Why?
|
| Malate Dehydrogenase | 2 | 2001 | 2 | 0.110 |
Why?
|
| Hypothalamus, Middle | 2 | 2005 | 2 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 594 | 0.110 |
Why?
|
| Glycosylation | 2 | 2012 | 17 | 0.110 |
Why?
|
| Phenols | 2 | 2007 | 5 | 0.110 |
Why?
|
| Thioredoxins | 2 | 2005 | 8 | 0.110 |
Why?
|
| Heart Ventricles | 2 | 2013 | 84 | 0.110 |
Why?
|
| Leukocytes | 2 | 1985 | 31 | 0.110 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2005 | 5 | 0.110 |
Why?
|
| Protein Folding | 2 | 2005 | 16 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 17 | 0.110 |
Why?
|
| Exercise | 1 | 2018 | 398 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2014 | 6 | 0.110 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2014 | 3 | 0.110 |
Why?
|
| DNA | 2 | 2012 | 97 | 0.110 |
Why?
|
| Disulfides | 2 | 2005 | 10 | 0.110 |
Why?
|
| Osteogenesis | 1 | 2015 | 102 | 0.110 |
Why?
|
| Models, Chemical | 2 | 2005 | 42 | 0.110 |
Why?
|
| Heart Failure | 2 | 2012 | 141 | 0.110 |
Why?
|
| Subcutaneous Fat | 1 | 2014 | 8 | 0.110 |
Why?
|
| Dementia | 1 | 2018 | 388 | 0.110 |
Why?
|
| Ataxin-3 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Enzyme Stability | 1 | 2013 | 4 | 0.110 |
Why?
|
| Endoplasmic Reticulum-Associated Degradation | 1 | 2013 | 2 | 0.110 |
Why?
|
| Lysine | 1 | 2013 | 14 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2014 | 21 | 0.100 |
Why?
|
| Protein Transport | 1 | 2013 | 29 | 0.100 |
Why?
|
| Half-Life | 2 | 2004 | 11 | 0.100 |
Why?
|
| Behavior, Animal | 1 | 2013 | 47 | 0.100 |
Why?
|
| Cerebral Ventricles | 1 | 2013 | 17 | 0.100 |
Why?
|
| Myelin Sheath | 1 | 2013 | 21 | 0.100 |
Why?
|
| Ventricular Dysfunction | 1 | 2013 | 1 | 0.100 |
Why?
|
| Weight Gain | 2 | 2011 | 59 | 0.100 |
Why?
|
| Corticosterone | 1 | 1993 | 2 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 2 | 2004 | 7 | 0.100 |
Why?
|
| Respiration | 1 | 2013 | 29 | 0.100 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1993 | 1 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2015 | 109 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 363 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 17 | 0.100 |
Why?
|
| Thyrotrophs | 1 | 2013 | 1 | 0.100 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 198 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 36 | 0.100 |
Why?
|
| Heterozygote | 2 | 2022 | 89 | 0.100 |
Why?
|
| Doxorubicin | 1 | 2013 | 57 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 246 | 0.100 |
Why?
|
| Heptanoic Acids | 1 | 2012 | 4 | 0.100 |
Why?
|
| Body Temperature | 5 | 2009 | 40 | 0.100 |
Why?
|
| Absorptiometry, Photon | 4 | 2007 | 79 | 0.100 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2007 | 35 | 0.100 |
Why?
|
| Pyrroles | 1 | 2012 | 23 | 0.100 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 3 | 2008 | 3 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 104 | 0.100 |
Why?
|
| Orphan Nuclear Receptors | 2 | 2010 | 2 | 0.100 |
Why?
|
| Child | 6 | 2021 | 1171 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Middle Cerebral Artery | 1 | 2012 | 8 | 0.100 |
Why?
|
| Cloning, Molecular | 2 | 2003 | 26 | 0.100 |
Why?
|
| Hypothermia | 1 | 2012 | 5 | 0.100 |
Why?
|
| Recovery of Function | 1 | 2013 | 246 | 0.100 |
Why?
|
| Neuropeptide Y | 4 | 2008 | 5 | 0.090 |
Why?
|
| Lumbar Vertebrae | 1 | 1997 | 357 | 0.090 |
Why?
|
| Ligases | 2 | 2003 | 7 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 43 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 3 | 0.090 |
Why?
|
| Isoproterenol | 1 | 2012 | 13 | 0.090 |
Why?
|
| Muscle Proteins | 1 | 2012 | 22 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2002 | 14 | 0.090 |
Why?
|
| Transcription Factor CHOP | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tunicamycin | 1 | 2011 | 2 | 0.090 |
Why?
|
| Thapsigargin | 1 | 2011 | 4 | 0.090 |
Why?
|
| Respiratory Mucosa | 1 | 2011 | 3 | 0.090 |
Why?
|
| Protein Stability | 1 | 2011 | 4 | 0.090 |
Why?
|
| Proteolysis | 1 | 2011 | 6 | 0.090 |
Why?
|
| Selenoproteins | 2 | 2002 | 3 | 0.090 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 10 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 1441 | 0.090 |
Why?
|
| Age Factors | 4 | 2013 | 641 | 0.090 |
Why?
|
| Brain Ischemia | 1 | 2012 | 61 | 0.090 |
Why?
|
| Kidney Tubules | 1 | 2011 | 6 | 0.090 |
Why?
|
| Epithelial Cells | 1 | 2011 | 70 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2011 | 13 | 0.090 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2021 | 10 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 9 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2011 | 44 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2021 | 48 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2020 | 245 | 0.080 |
Why?
|
| Risk Factors | 4 | 2020 | 1998 | 0.080 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 24 | 0.080 |
Why?
|
| Metabolism | 1 | 2010 | 5 | 0.080 |
Why?
|
| Cells | 1 | 2010 | 3 | 0.080 |
Why?
|
| Consensus | 2 | 2021 | 85 | 0.080 |
Why?
|
| Wnt Proteins | 1 | 2010 | 20 | 0.080 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2010 | 6 | 0.080 |
Why?
|
| HIV-1 | 2 | 2002 | 202 | 0.080 |
Why?
|
| Phospholipid Transfer Proteins | 1 | 2009 | 1 | 0.080 |
Why?
|
| Iopanoic Acid | 2 | 2000 | 2 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 123 | 0.080 |
Why?
|
| Cognitive Dysfunction | 1 | 2016 | 727 | 0.080 |
Why?
|
| Graves Disease | 1 | 1989 | 3 | 0.080 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2009 | 1 | 0.080 |
Why?
|
| Creatine Kinase, Mitochondrial Form | 1 | 2009 | 1 | 0.080 |
Why?
|
| Transcription Factor RelA | 2 | 2006 | 17 | 0.080 |
Why?
|
| Genes | 1 | 1988 | 6 | 0.070 |
Why?
|
| Melanocortins | 1 | 2008 | 1 | 0.070 |
Why?
|
| Fetus | 1 | 2008 | 31 | 0.070 |
Why?
|
| Catecholamines | 2 | 2009 | 7 | 0.070 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2008 | 2 | 0.070 |
Why?
|
| Luminescent Proteins | 1 | 2008 | 6 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 8 | 0.070 |
Why?
|
| Antithyroid Agents | 1 | 2008 | 1 | 0.070 |
Why?
|
| Pituitary Adenylate Cyclase-Activating Polypeptide | 1 | 2007 | 4 | 0.070 |
Why?
|
| Ischemia | 1 | 2008 | 23 | 0.070 |
Why?
|
| Gastric Bypass | 1 | 2009 | 68 | 0.070 |
Why?
|
| Hypoxia | 1 | 2008 | 30 | 0.070 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2006 | 24 | 0.070 |
Why?
|
| Surface Properties | 1 | 2008 | 125 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 4 | 2014 | 86 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 50 | 0.070 |
Why?
|
| Hormone Antagonists | 1 | 2007 | 1 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2007 | 5 | 0.070 |
Why?
|
| Spermatids | 1 | 2007 | 2 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2005 | 26 | 0.070 |
Why?
|
| Thyrotoxicosis | 2 | 2004 | 2 | 0.070 |
Why?
|
| Holoenzymes | 1 | 2007 | 1 | 0.070 |
Why?
|
| Protein Structure, Quaternary | 1 | 2007 | 5 | 0.070 |
Why?
|
| Palmitic Acid | 1 | 2007 | 4 | 0.070 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase Type II | 1 | 2007 | 1 | 0.070 |
Why?
|
| Chalcones | 1 | 2007 | 2 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 6 | 0.070 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 35 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 36 | 0.070 |
Why?
|
| Brucella abortus | 1 | 2006 | 1 | 0.070 |
Why?
|
| Buffaloes | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cation Transport Proteins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Brucellosis | 1 | 2006 | 4 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 68 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2006 | 54 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1050 | 0.060 |
Why?
|
| Osteocalcin | 2 | 2008 | 27 | 0.060 |
Why?
|
| Sterol Esterase | 1 | 2006 | 1 | 0.060 |
Why?
|
| Acromegaly | 1 | 2006 | 2 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 124 | 0.060 |
Why?
|
| Cycloheximide | 2 | 2003 | 7 | 0.060 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2006 | 9 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2021 | 813 | 0.060 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 31 | 0.060 |
Why?
|
| Plasmids | 2 | 2003 | 43 | 0.060 |
Why?
|
| Retinoid X Receptors | 1 | 2005 | 3 | 0.060 |
Why?
|
| Selenium Radioisotopes | 2 | 2003 | 2 | 0.060 |
Why?
|
| Receptors, Thyrotropin | 2 | 2021 | 5 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 16 | 0.060 |
Why?
|
| Arcuate Nucleus of Hypothalamus | 1 | 2005 | 1 | 0.060 |
Why?
|
| Immunodominant Epitopes | 2 | 2002 | 3 | 0.060 |
Why?
|
| Physostigmine | 1 | 2005 | 1 | 0.060 |
Why?
|
| Somatostatin | 1 | 2005 | 2 | 0.060 |
Why?
|
| Antigen Presentation | 2 | 2002 | 14 | 0.060 |
Why?
|
| Metoclopramide | 1 | 2005 | 4 | 0.060 |
Why?
|
| Iduronidase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2005 | 6 | 0.060 |
Why?
|
| Elongin | 1 | 2005 | 2 | 0.060 |
Why?
|
| beta-Transducin Repeat-Containing Proteins | 1 | 2005 | 2 | 0.060 |
Why?
|
| Chick Embryo | 1 | 2005 | 15 | 0.060 |
Why?
|
| Protein Subunits | 1 | 2005 | 17 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2005 | 18 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 34 | 0.060 |
Why?
|
| Lipid Peroxidation | 1 | 2005 | 6 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 1987 | 205 | 0.060 |
Why?
|
| Dopamine | 1 | 2005 | 78 | 0.060 |
Why?
|
| Cell Survival | 2 | 2015 | 102 | 0.060 |
Why?
|
| Feeding Behavior | 1 | 2005 | 79 | 0.060 |
Why?
|
| Reactive Oxygen Species | 3 | 2011 | 106 | 0.060 |
Why?
|
| Uncoupling Protein 2 | 2 | 2003 | 2 | 0.060 |
Why?
|
| Chondrocytes | 1 | 2005 | 97 | 0.060 |
Why?
|
| Genotype | 2 | 2020 | 246 | 0.050 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 866 | 0.050 |
Why?
|
| Bibliometrics | 1 | 2004 | 23 | 0.050 |
Why?
|
| Methimazole | 2 | 2002 | 2 | 0.050 |
Why?
|
| Bundle-Branch Block | 1 | 2003 | 4 | 0.050 |
Why?
|
| Logistic Models | 2 | 2021 | 358 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2003 | 16 | 0.050 |
Why?
|
| Glycoside Hydrolases | 1 | 2003 | 1 | 0.050 |
Why?
|
| Plant Proteins | 1 | 2003 | 2 | 0.050 |
Why?
|
| Gene Library | 1 | 2003 | 6 | 0.050 |
Why?
|
| Tibia | 1 | 2005 | 198 | 0.050 |
Why?
|
| Dobutamine | 2 | 2014 | 2 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 7 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2003 | 12 | 0.050 |
Why?
|
| Adipose Tissue, White | 2 | 2016 | 4 | 0.050 |
Why?
|
| Mast Cells | 1 | 1983 | 18 | 0.050 |
Why?
|
| Dithiothreitol | 1 | 2003 | 3 | 0.050 |
Why?
|
| Immunosorbent Techniques | 1 | 2003 | 3 | 0.050 |
Why?
|
| Isotope Labeling | 1 | 2003 | 3 | 0.050 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2003 | 10 | 0.050 |
Why?
|
| Receptors, Neuropeptide Y | 1 | 2002 | 1 | 0.050 |
Why?
|
| Clathrin | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glutathione | 1 | 2002 | 23 | 0.050 |
Why?
|
| Gene Products, gag | 1 | 2002 | 3 | 0.050 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2002 | 3 | 0.050 |
Why?
|
| HLA-A2 Antigen | 1 | 2002 | 5 | 0.050 |
Why?
|
| Endocytosis | 1 | 2002 | 16 | 0.050 |
Why?
|
| HIV Antigens | 1 | 2002 | 12 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 89 | 0.050 |
Why?
|
| Galactose | 1 | 2002 | 3 | 0.050 |
Why?
|
| Parturition | 1 | 2022 | 2 | 0.050 |
Why?
|
| Viral Proteins | 1 | 2002 | 12 | 0.050 |
Why?
|
| Songbirds | 1 | 2002 | 2 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2002 | 22 | 0.050 |
Why?
|
| Thiazolidinediones | 2 | 2015 | 7 | 0.050 |
Why?
|
| Pyridines | 1 | 2022 | 27 | 0.050 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 13 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2012 | 13 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2020 | 578 | 0.050 |
Why?
|
| Leydig Cells | 1 | 2002 | 1 | 0.050 |
Why?
|
| Adenylyl Cyclases | 2 | 2004 | 10 | 0.050 |
Why?
|
| Cholesterol, Dietary | 1 | 1981 | 1 | 0.050 |
Why?
|
| Desiccation | 1 | 2021 | 2 | 0.050 |
Why?
|
| Puromycin Aminonucleoside | 1 | 2021 | 5 | 0.050 |
Why?
|
| Time | 1 | 2001 | 14 | 0.050 |
Why?
|
| Dioxoles | 1 | 2001 | 12 | 0.050 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2021 | 15 | 0.050 |
Why?
|
| Placebos | 1 | 2021 | 64 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 64 | 0.040 |
Why?
|
| Selenium | 1 | 2001 | 7 | 0.040 |
Why?
|
| Radioimmunoassay | 4 | 2007 | 19 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2022 | 59 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 29 | 0.040 |
Why?
|
| Gene Products, nef | 1 | 2001 | 1 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 157 | 0.040 |
Why?
|
| Oxygen | 1 | 2001 | 58 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2022 | 133 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2001 | 12 | 0.040 |
Why?
|
| Uncoupling Protein 3 | 1 | 2001 | 1 | 0.040 |
Why?
|
| Proteinuria | 1 | 2021 | 48 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 113 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2001 | 18 | 0.040 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 1 | 0.040 |
Why?
|
| Paired Box Transcription Factors | 1 | 2021 | 3 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 168 | 0.040 |
Why?
|
| Phylogeny | 1 | 2001 | 44 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 33 | 0.040 |
Why?
|
| Intelligence Tests | 1 | 2021 | 13 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 58 | 0.040 |
Why?
|
| Gene Editing | 1 | 2021 | 7 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 12 | 0.040 |
Why?
|
| Behavioral Symptoms | 1 | 2021 | 11 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 11 | 0.040 |
Why?
|
| Digitonin | 1 | 2000 | 1 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2000 | 21 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2000 | 18 | 0.040 |
Why?
|
| Heredity | 1 | 2020 | 5 | 0.040 |
Why?
|
| Epitopes | 1 | 2000 | 39 | 0.040 |
Why?
|
| Weight Loss | 1 | 2001 | 122 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 50 | 0.040 |
Why?
|
| Membrane Potentials | 1 | 2001 | 169 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2001 | 39 | 0.040 |
Why?
|
| Cell Membrane Permeability | 1 | 2000 | 51 | 0.040 |
Why?
|
| Cartilage | 1 | 2021 | 70 | 0.040 |
Why?
|
| Length of Stay | 1 | 2022 | 305 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 169 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 109 | 0.040 |
Why?
|
| Peptides | 1 | 2000 | 89 | 0.040 |
Why?
|
| Body Height | 1 | 1999 | 31 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 55 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2020 | 243 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2020 | 220 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 15 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2007 | 132 | 0.040 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2019 | 8 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 102 | 0.040 |
Why?
|
| Adrenergic Antagonists | 1 | 1999 | 1 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 290 | 0.040 |
Why?
|
| Pilocarpine | 1 | 2018 | 1 | 0.040 |
Why?
|
| Muscarinic Agonists | 1 | 2018 | 1 | 0.040 |
Why?
|
| Protein Precursors | 3 | 2002 | 18 | 0.040 |
Why?
|
| Cell Death | 1 | 2018 | 34 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 116 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2011 | 384 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 29 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 37 | 0.040 |
Why?
|
| Health Personnel | 1 | 2019 | 87 | 0.040 |
Why?
|
| HIV Infections | 1 | 2002 | 424 | 0.040 |
Why?
|
| Enzymes | 1 | 1998 | 5 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 1998 | 14 | 0.040 |
Why?
|
| Molecular Mimicry | 1 | 2017 | 3 | 0.040 |
Why?
|
| Liver X Receptors | 2 | 2010 | 2 | 0.030 |
Why?
|
| Epithelium | 1 | 2017 | 26 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2017 | 11 | 0.030 |
Why?
|
| Ovariectomy | 1 | 1997 | 26 | 0.030 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 1997 | 5 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 103 | 0.030 |
Why?
|
| North America | 1 | 1997 | 32 | 0.030 |
Why?
|
| MyoD Protein | 1 | 2017 | 1 | 0.030 |
Why?
|
| Myogenic Regulatory Factor 5 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Jejunoileal Bypass | 2 | 1988 | 2 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 87 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2013 | 540 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 251 | 0.030 |
Why?
|
| Perilipin-1 | 2 | 2007 | 2 | 0.030 |
Why?
|
| Inflammation | 1 | 2018 | 235 | 0.030 |
Why?
|
| Citrate (si)-Synthase | 1 | 2016 | 2 | 0.030 |
Why?
|
| Hindlimb Suspension | 1 | 2016 | 2 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2016 | 5 | 0.030 |
Why?
|
| Efficiency | 1 | 2016 | 20 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2016 | 66 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 15 | 0.030 |
Why?
|
| Enzyme Induction | 2 | 2008 | 19 | 0.030 |
Why?
|
| Thoracic Surgery | 1 | 2016 | 26 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2016 | 76 | 0.030 |
Why?
|
| Agouti-Related Protein | 2 | 2008 | 2 | 0.030 |
Why?
|
| Heart Rate | 2 | 2009 | 104 | 0.030 |
Why?
|
| Pyridones | 1 | 1995 | 10 | 0.030 |
Why?
|
| Dactinomycin | 2 | 1992 | 6 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 15 | 0.030 |
Why?
|
| Camptothecin | 1 | 2015 | 3 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2015 | 8 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 5 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2015 | 11 | 0.030 |
Why?
|
| Alcohol Dehydrogenase | 1 | 2015 | 1 | 0.030 |
Why?
|
| Nitrosation | 1 | 2015 | 2 | 0.030 |
Why?
|
| Rabbits | 2 | 2013 | 168 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2015 | 4 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 25 | 0.030 |
Why?
|
| Osteoclasts | 1 | 2015 | 22 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 240 | 0.030 |
Why?
|
| Glycerolphosphate Dehydrogenase | 2 | 2001 | 2 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 2015 | 48 | 0.030 |
Why?
|
| Adrenal Cortex | 1 | 1994 | 3 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1994 | 10 | 0.030 |
Why?
|
| Disease Progression | 1 | 2016 | 525 | 0.030 |
Why?
|
| Bone Resorption | 1 | 2015 | 79 | 0.030 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2014 | 4 | 0.030 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 1994 | 14 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 1985 | 155 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 636 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1994 | 47 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2016 | 247 | 0.030 |
Why?
|
| Lac Operon | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sebaceous Glands | 1 | 2014 | 1 | 0.030 |
Why?
|
| Epidermis | 1 | 2014 | 3 | 0.030 |
Why?
|
| Alopecia | 1 | 2014 | 2 | 0.030 |
Why?
|
| Dermis | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2014 | 22 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 380 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 46 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 104 | 0.030 |
Why?
|
| Chicago | 1 | 2016 | 819 | 0.030 |
Why?
|
| Glucose Clamp Technique | 1 | 2013 | 1 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 1993 | 5 | 0.030 |
Why?
|
| Sympathectomy | 1 | 1993 | 3 | 0.030 |
Why?
|
| NADP | 1 | 1993 | 9 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 200 | 0.030 |
Why?
|
| Calcium | 2 | 1994 | 358 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 11 | 0.030 |
Why?
|
| Creatinine | 1 | 2013 | 40 | 0.030 |
Why?
|
| Denervation | 1 | 1993 | 20 | 0.030 |
Why?
|
| Research | 1 | 2013 | 36 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2013 | 31 | 0.020 |
Why?
|
| Sarcoplasmic Reticulum | 2 | 2002 | 157 | 0.020 |
Why?
|
| Uncoupling Agents | 2 | 1992 | 4 | 0.020 |
Why?
|
| Adrenergic beta-1 Receptor Agonists | 1 | 2012 | 2 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2012 | 12 | 0.020 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2012 | 6 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2013 | 181 | 0.020 |
Why?
|
| RNA | 1 | 1992 | 31 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2012 | 27 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 391 | 0.020 |
Why?
|
| Adenocarcinoma | 2 | 2007 | 135 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 86 | 0.020 |
Why?
|
| Sicily | 1 | 2011 | 1 | 0.020 |
Why?
|
| Enzyme Assays | 1 | 2011 | 1 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2011 | 7 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Pyloric Antrum | 1 | 1991 | 2 | 0.020 |
Why?
|
| Gastrins | 1 | 1991 | 4 | 0.020 |
Why?
|
| Jejunum | 1 | 1991 | 10 | 0.020 |
Why?
|
| Ileum | 1 | 1991 | 14 | 0.020 |
Why?
|
| GTP-Binding Proteins | 2 | 2004 | 9 | 0.020 |
Why?
|
| Hyperplasia | 2 | 1994 | 19 | 0.020 |
Why?
|
| Overweight | 1 | 2011 | 67 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2010 | 14 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2010 | 15 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2011 | 124 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2010 | 14 | 0.020 |
Why?
|
| Prevalence | 1 | 2011 | 384 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 2 | 0.020 |
Why?
|
| Tretinoin | 1 | 2010 | 15 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 19 | 0.020 |
Why?
|
| Chickens | 1 | 2010 | 32 | 0.020 |
Why?
|
| Hemodynamics | 2 | 2003 | 62 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 4 | 0.020 |
Why?
|
| Thiolester Hydrolases | 1 | 2009 | 3 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 73 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2009 | 7 | 0.020 |
Why?
|
| Postprandial Period | 1 | 2009 | 7 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2009 | 15 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2009 | 28 | 0.020 |
Why?
|
| Chromans | 1 | 2008 | 1 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1988 | 38 | 0.020 |
Why?
|
| Collagen Type X | 1 | 2008 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2008 | 4 | 0.020 |
Why?
|
| Stroke | 1 | 2011 | 240 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2009 | 145 | 0.020 |
Why?
|
| Indicators and Reagents | 2 | 2000 | 10 | 0.020 |
Why?
|
| Pancreas | 1 | 1988 | 30 | 0.020 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2008 | 1 | 0.020 |
Why?
|
| Gestational Age | 1 | 2008 | 73 | 0.020 |
Why?
|
| Intestines | 1 | 1988 | 76 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 7 | 0.020 |
Why?
|
| Seminiferous Epithelium | 1 | 2007 | 1 | 0.020 |
Why?
|
| Spermatogenesis | 1 | 2007 | 1 | 0.020 |
Why?
|
| Computer Systems | 1 | 2007 | 7 | 0.020 |
Why?
|
| Spermatozoa | 1 | 2007 | 8 | 0.020 |
Why?
|
| Cell Count | 2 | 2002 | 71 | 0.020 |
Why?
|
| Citric Acid Cycle | 1 | 2007 | 1 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2007 | 4 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2007 | 4 | 0.020 |
Why?
|
| Glucosamine | 1 | 2007 | 3 | 0.020 |
Why?
|
| Sweetening Agents | 1 | 2007 | 5 | 0.020 |
Why?
|
| Amino Acids | 1 | 2007 | 19 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 836 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2007 | 11 | 0.020 |
Why?
|
| Restraint, Physical | 1 | 1987 | 8 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1429 | 0.020 |
Why?
|
| Complement Fixation Tests | 1 | 2006 | 1 | 0.020 |
Why?
|
| Reactive Nitrogen Species | 1 | 2006 | 1 | 0.020 |
Why?
|
| Agglutination Tests | 1 | 2006 | 4 | 0.020 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 4 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2006 | 7 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 17 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2006 | 5 | 0.020 |
Why?
|
| Skin Tests | 1 | 2006 | 7 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2006 | 19 | 0.020 |
Why?
|
| Random Allocation | 1 | 2007 | 105 | 0.020 |
Why?
|
| Homozygote | 1 | 2006 | 13 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2006 | 12 | 0.020 |
Why?
|
| Motor Activity | 1 | 2009 | 276 | 0.020 |
Why?
|
| Monocytes | 1 | 2006 | 49 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2006 | 1 | 0.020 |
Why?
|
| Sulfasalazine | 1 | 2006 | 3 | 0.020 |
Why?
|
| Luciferases | 1 | 2006 | 25 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 11 | 0.020 |
Why?
|
| Systole | 1 | 2006 | 13 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2009 | 212 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cholic Acid | 1 | 2006 | 1 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2006 | 12 | 0.020 |
Why?
|
| Organic Chemicals | 1 | 2005 | 4 | 0.020 |
Why?
|
| Retinoids | 1 | 2005 | 5 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 2006 | 17 | 0.020 |
Why?
|
| Benzoates | 1 | 2005 | 5 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2005 | 19 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2006 | 23 | 0.020 |
Why?
|
| Agouti Signaling Protein | 1 | 2005 | 1 | 0.020 |
Why?
|
| Liver Glycogen | 1 | 1985 | 1 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1985 | 2 | 0.010 |
Why?
|
| Goiter | 1 | 1985 | 3 | 0.010 |
Why?
|
| Cocaine | 1 | 2005 | 31 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 1985 | 5 | 0.010 |
Why?
|
| Muscles | 1 | 1985 | 56 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1985 | 31 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 17 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 64 | 0.010 |
Why?
|
| Neutrophils | 1 | 1985 | 94 | 0.010 |
Why?
|
| Pituitary Gland, Anterior | 1 | 2003 | 2 | 0.010 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2003 | 3 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 73 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2003 | 34 | 0.010 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 1983 | 1 | 0.010 |
Why?
|
| Cromolyn Sodium | 1 | 1983 | 2 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 38 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 2003 | 68 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 107 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2004 | 88 | 0.010 |
Why?
|
| Photochemistry | 1 | 2003 | 1 | 0.010 |
Why?
|
| Carbocyanines | 1 | 2003 | 2 | 0.010 |
Why?
|
| Solubility | 1 | 2003 | 25 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 32 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 34 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2002 | 1 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 7 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 2002 | 4 | 0.010 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2002 | 4 | 0.010 |
Why?
|
| Epididymis | 1 | 2002 | 6 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 38 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2002 | 9 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2002 | 17 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 452 | 0.010 |
Why?
|
| Sertoli Cells | 1 | 2002 | 1 | 0.010 |
Why?
|
| Androstane-3,17-diol | 1 | 2002 | 1 | 0.010 |
Why?
|
| Testis | 1 | 2002 | 9 | 0.010 |
Why?
|
| Cimetidine | 1 | 1981 | 1 | 0.010 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2001 | 3 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 2001 | 4 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2001 | 7 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2001 | 13 | 0.010 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 3 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 20 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2001 | 36 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 14 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2001 | 58 | 0.010 |
Why?
|
| Femur | 1 | 2003 | 304 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 2001 | 49 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 289 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 6 | 0.010 |
Why?
|
| Cysteine | 1 | 2000 | 8 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2000 | 11 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2001 | 118 | 0.010 |
Why?
|
| Infant | 1 | 2001 | 486 | 0.010 |
Why?
|
| Adenosine Diphosphate Ribose | 1 | 1996 | 1 | 0.010 |
Why?
|
| Phenylisopropyladenosine | 1 | 1996 | 1 | 0.010 |
Why?
|
| Adenylate Cyclase Toxin | 1 | 1996 | 1 | 0.010 |
Why?
|
| Virulence Factors, Bordetella | 1 | 1996 | 2 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 1996 | 3 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1996 | 4 | 0.010 |
Why?
|
| Vinblastine | 1 | 1996 | 7 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 17 | 0.010 |
Why?
|
| Etoposide | 1 | 1996 | 27 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 16 | 0.010 |
Why?
|
| Carboplatin | 1 | 1996 | 24 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1996 | 153 | 0.010 |
Why?
|
| Cause of Death | 1 | 1996 | 57 | 0.010 |
Why?
|
| Cisplatin | 1 | 1996 | 60 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 1996 | 2 | 0.010 |
Why?
|
| CHO Cells | 1 | 1996 | 11 | 0.010 |
Why?
|
| Calibration | 1 | 1996 | 16 | 0.010 |
Why?
|
| Cricetinae | 1 | 1996 | 34 | 0.010 |
Why?
|
| Reference Standards | 1 | 1996 | 22 | 0.010 |
Why?
|
| Milrinone | 1 | 1995 | 2 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1996 | 164 | 0.010 |
Why?
|
| Acute Disease | 1 | 1995 | 168 | 0.010 |
Why?
|
| Cushing Syndrome | 1 | 1994 | 2 | 0.010 |
Why?
|
| Hyperandrogenism | 1 | 1994 | 2 | 0.010 |
Why?
|
| Hyperaldosteronism | 1 | 1994 | 3 | 0.010 |
Why?
|
| Myelin Basic Protein | 1 | 1994 | 20 | 0.010 |
Why?
|
| Nucleic Acid Precursors | 1 | 1992 | 1 | 0.010 |
Why?
|
| Prazosin | 1 | 1991 | 2 | 0.010 |
Why?
|
| Calorimetry | 1 | 1991 | 4 | 0.010 |
Why?
|
| Amylases | 1 | 1988 | 5 | 0.000 |
Why?
|
| Lipase | 1 | 1988 | 4 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1985 | 14 | 0.000 |
Why?
|
| Stomach | 1 | 1985 | 14 | 0.000 |
Why?
|